Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Zanzalintinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Giving zanzalintinib may be safe, tolerable, and/or effective in treating patients with advanced liver cancer.

NCT Number	NCT07042919
Lead Sponsor	Devalingam Mahalingam Collaborators: National Cancer Institute (NCI)
Conditions	Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Enrollment	59 participants
Start Date	2026-03-30
Primary Completion	2029-03-04 (estimated)
Study Completion	2031-03-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-25